IMPROVED AUDIO
Robert Lustig, MD discusses his previous presentation at Emery Pharma with the CEO of Emery Pharma, Ron Najafi, Ph.D. In summary, Dr. Lustig discusses the rise of type 2 diabetes in children and challenges the notion that it is a chronic, unrelenting, and genetic disease. He argues that the increase in type 2 diabetes is due to exposure to certain factors, primarily ultra-processed foods containing high amounts of sugar, trans fats, and other substances that affect Liver, the microbiome and promote inflammation. Dr. Lustig also emphasizes the importance of distinguishing between metabolically healthy and unhealthy obesity and suggests biomarkers such as waist circumference, fasting insulin levels, uric acid levels, and ALT levels to assess metabolic health. Regarding statins, Dr. Lustig acknowledges their effectiveness for secondary prevention in individuals who have already experienced a heart attack but questions their use for primary prevention. He mentions that statins can have mitochondrial toxicity and may increase the risk of diabetes. Lastly, Dr. Lustig suggests enjoying desserts in moderation and as an occasional treat, while advocating for the reduction of sugar in processed foods.
we encourage you to watch other video’s recorded at Emery Pharma with Professor Lustig:
About Emery Pharma:
Emery Pharma is a full-service contract research laboratory, supporting the end-to-end development of small molecule drugs, biologics, biosimilars, gene therapy, botanicals, and more.
Emery Pharma’s premium services include analytical, bioanalytical solutions, microbiology & cell biology services, drug and impurity characterization, and general R&D and cGMP/GLP support.
At Emery Pharma, our focus is to find innovative solutions for our Clients’ toughest challenges and tailoring those solutions to fit each Client’s unique needs. Our experienced scientific team will manage the process: from drug discovery, proof-of-concept, data management, data analysis, to gathering insights. The team excels at solving scientific challenges, and addressing any issues early in the process, so Clients don’t experience unnecessary setbacks.
Emery Pharma’s experienced chemists and biologists deploy state-of-the-art technology. Instrumentation ranges from high-resolution mass spec (Orbitrap), Triple quad LC-MS/MS, GC-MS, Preparative HPLC, and 400 MHz multinuclear NMR.
Contact us: [email protected]
https://emerypharma.com/
source
